-- Potential proceeds would be received upon full cash exercise of warrants -- 

ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has entered into a securities purchase agreement (the “Purchase Agreement”) for a $30 million private placement with certain accredited investors. The financing was led by new institutional investor Nantahala Capital, with participation from additional new healthcare-focused funds, including Rosalind Advisors, Inc., as well as members of Femasys’ management team. The private placement is subject to customary closing conditions and is expected to close on or around August 10, 2026.